{"id":59647,"date":"2026-03-16T20:15:48","date_gmt":"2026-03-16T12:15:48","guid":{"rendered":"https:\/\/flcube.com\/?p=59647"},"modified":"2026-03-16T20:15:50","modified_gmt":"2026-03-16T12:15:50","slug":"abb-bio-tech-partners-with-walvax-for-overseas-push-first-china-approved-trivalent-subunit-influenza-vaccine-targets-global-markets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59647","title":{"rendered":"Ab&B Bio-Tech Partners with Walvax for Overseas Push \u2013 First China-Approved Trivalent Subunit Influenza Vaccine Targets Global Markets"},"content":{"rendered":"\n

Ab&B Bio-Tech Co., Ltd.<\/strong> (HKG: 2627<\/a>) entered into a strategic partnership<\/strong> with Walvax Biotechnology Co., Ltd.<\/strong> (SHE: 300142<\/a>) to accelerate registration, sales, and commercialization<\/strong> of Ab&B Bio’s trivalent subunit influenza vaccine<\/strong> in overseas markets<\/strong>. The collaboration leverages Walvax’s international vaccine distribution infrastructure<\/strong> to expand the global footprint of China’s first and only<\/strong> trivalent subunit influenza vaccine approved for individuals aged six months and above<\/strong>.<\/p>\n\n\n\n

Partnership Framework<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Parties<\/strong><\/td>Ab&B Bio-Tech Co., Ltd. (HKG: 2627) + Walvax Biotechnology Co., Ltd. (SHE: 300142)<\/td><\/tr>
Agreement Type<\/strong><\/td>Strategic cooperation (registration + commercialization)<\/td><\/tr>
Product<\/strong><\/td>Trivalent subunit influenza vaccine<\/td><\/tr>
Geographic Scope<\/strong><\/td>Overseas markets (ex-China)<\/td><\/tr>
Signing Date<\/strong><\/td>Week of 9\u202fMar\u202f2026<\/td><\/tr>
Financial Terms<\/strong><\/td>Not disclosed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile<\/h2>\n\n\n\n
Attribute<\/th>Vaccine Specification<\/th><\/tr><\/thead>
Composition<\/strong><\/td>Trivalent subunit influenza vaccine<\/td><\/tr>
Target Population<\/strong><\/td>Individuals \u22656 months of age<\/strong> (broad age indication)<\/td><\/tr>
China Approval<\/strong><\/td>January 2026<\/strong> \u2013 first and only in category<\/td><\/tr>
Market Position<\/strong><\/td>China’s first trivalent subunit influenza vaccine<\/strong> with pediatric indication<\/td><\/tr>
Technology<\/strong><\/td>Subunit formulation vs. split virion or live-attenuated alternatives<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale & Market Context<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
China Vaccine Export Trend<\/strong><\/td>Domestic innovators increasingly seeking WHO prequalification and emerging market registrations to offset China price pressure<\/td><\/tr>
Walvax Capabilities<\/strong><\/td>Established vaccine exporter with COVID-19, HPV, and pneumococcal<\/strong> international track record; strong presence in Southeast Asia, Africa, and Latin America<\/td><\/tr>
Subunit Differentiation<\/strong><\/td>Favorable safety profile (no egg protein, reduced reactogenicity) supports premium positioning vs. traditional split vaccines in pediatric and elderly segments<\/td><\/tr>
Global Influenza Market<\/strong><\/td>$6+ billion annually<\/strong>; subunit vaccines gaining share in developed markets (Europe, Japan) due to tolerability advantages<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Sanofi Flublok (recombinant) and Seqirus subunit products dominate globally; Ab&B Bio positions as cost-competitive alternative<\/strong> for emerging markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n